Stockreport

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics, Inc.  (CGTX) 
PDF -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. [Read more]